Grifols streamlines its global plasma network with the closure of 29 donation centers in the U.S.

Barcelona, Spain, April 24, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced a targeted optimization of its plasma donation center network in the United States, where the company is the leading plasma operator with more than 300 centers. This initiative is part of a broader, ongoing strategy to enhance the productivity, efficiency and long-term sustainability of its U.S. plasma platform.

The initiative includes the closure of 29 centers, alongside the consolidation of operations into higher-performing locations. This process is designed to enhance productivity per center, improve plasma collection efficiency and overall yield across the network and reinforce the resilience of plasma supply, in line with Grifols’ strategic focus on delivering margin-led EBITDA growth.

The optimization will be implemented over the coming weeks, with affected centers operating during a short transition to ensure a smooth transition for donors while reinforcing the performance of the overall network. Donors from affected centers will be redirected to nearby Grifols locations, ensuring continuity and maintaining a safe, high-quality donation experience.

Despite this footprint optimization, Grifols expects to grow its overall plasma collection volumes in the US, supported by higher productivity per center and improved utilization of its network.

Jordi Balsells, President Plasma Procurement, said: “We have a clear opportunity to drive efficiencies with our US plasma collections and thereby contribute to our margin improvement objective whilst continuing to grow US plasma collection volumes to support the continued strong growth prospects of plasma derives medicines in the US.”

The recent game-changing EMA approval of highly scalable source plasma from Egypt, together with the largest plasma collection network in Europe, offers a clear opportunity to reduce the use of US plasma for ex-us markets in the future and focus growing US collections on the US market with its strong growth outlook. Further, increasing productivity and collections by center, as well as improved network utilization, allows for streamlining of Grifols’ donor center network in the US whilst continuing to grow the US plasma collection volumes to support the strong growth needs for plasma derived medicines in the US market.

Performance-driven optimization and scalable U.S. platform

This decision follows a rigorous and continuous performance review of the whole U.S network. Over the past year, Grifols has implemented multiple operational initiatives aimed at enhancing performance across its plasma centers. Building on this process, the company is now prioritizing centers with stronger performance and greater growth potential, reallocating resources to those locations where it can deliver higher productivity, improved efficiency and more consistent results over time.

Plasma collection in the U.S. is the foundation of Grifols’ vertically integrated model, supported by significant industrial operations in California and North Carolina, a workforce of more than 14,000 employees nationwide. This combination of scale, full vertical integration and a nationwide footprint underpins a highly resilient platform capable of sustaining long-term growth and value creation, supported by ongoing improvements in donor experience and retention across the network.